首页|免疫检查点抑制剂治疗晚期肝细胞癌的研究进展

免疫检查点抑制剂治疗晚期肝细胞癌的研究进展

扫码查看
肝细胞癌(hepatocellular carcinoma,HCC)是我国常见的恶性肿瘤,起病隐匿,病人就诊时多为中晚期,失去手术机会,预后极差.近年来,以免疫检查点抑制剂(immune checkpoint in-hibitors,ICIs)为代表的免疫治疗在晚期HCC治疗中日益普及,但仍有许多病人治疗效果不理想.ICIs与其他治疗的联合方案已成为治疗晚期HCC最有潜力的策略.本文对ICIs单药或联合其他治疗在晚期HCC治疗中的最新研究进展进行综述.
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Hepatocellular carcinoma(HCC),frequently diagnosed at advanced stages in China due to insidious onset,faces a dismal prognosis with limited surgical feasibility.The advent of immunotherapy,particularly immune checkpoint inhibitors(ICIs),introduces novel therapeutic prospects,albeit with variable efficacies.The combination of ICIs with various therapeutic strategies is increasingly recognized as a critical approach in the management of advanced HCC.This article reviews recent advances in ICIs for advanced hepatocellular carcinoma and discusses the future prospects of immunotherapy.

advanced hepatocellular carcinomaimmune checkpoint inhibitorscombination therapy

周一、梁宾勇、肖震宇

展开 >

430030 武汉,华中科技大学同济医学院附属同济医院肝脏外科

晚期肝细胞癌 免疫检查点抑制剂 联合治疗

2024

临床外科杂志
中华医学会湖北分会

临床外科杂志

CSTPCD
影响因子:0.716
ISSN:1005-6483
年,卷(期):2024.32(3)
  • 31